CA2223573A1 - Use of hydroxyethyl starch to prevent post surgical adhesion and as an intracavity carrier device - Google Patents

Use of hydroxyethyl starch to prevent post surgical adhesion and as an intracavity carrier device

Info

Publication number
CA2223573A1
CA2223573A1 CA002223573A CA2223573A CA2223573A1 CA 2223573 A1 CA2223573 A1 CA 2223573A1 CA 002223573 A CA002223573 A CA 002223573A CA 2223573 A CA2223573 A CA 2223573A CA 2223573 A1 CA2223573 A1 CA 2223573A1
Authority
CA
Canada
Prior art keywords
agent
composition according
hydroxyethyl starch
hes
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002223573A
Other languages
French (fr)
Other versions
CA2223573C (en
Inventor
Gere Stodder Dizerega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23915271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2223573(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2223573A1 publication Critical patent/CA2223573A1/en
Application granted granted Critical
Publication of CA2223573C publication Critical patent/CA2223573C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

Hydroxyethyl starch (HES) and use thereof in methods are provided for reducing or preventing adhesion formation between tissue surfaces, e.g., organ surfaces, in body cavities following surgical procedures and for drug delivery. HES may be used as an absorbable mechanical barrier alone or in combination with one or more anti-adhesion formation compounds for application to injured areas of tissues, e.g., organs, situated in body cavities such as the peritoneal, pelvic, pleural cavity, central nervous system and interligamentous space. HES may also be used as an intracavity carrier device for delivery of pharmaceutically active agents.

Claims (11)

1. Use of a hydroxyethyl starch in the preparation of a medicament for a method for reducing or preventing formation of post-surgical adhesions between tissue surfaces in a body cavity, said method comprising administering an effective amount of said medicament for a period of time sufficient to permit tissue repair.
2. A use according to claim 1, wherein said tissue repair comprises re-epithelization.
3. A use according to claim 1, wherein said tissue repair comprises mesothelial repair.
4. A use according to claim 1, wherein said hydroxyethyl starch comprises an amylopectin having hydroxyethyl groups which are substituted on a molar ratioranging between 0.1 and 0.8 of a hydroxyethyl group per glucopyranose unit.
5. A use according to claim 4, wherein said hydroxyethyl starch comprises amylopectin monomers of molecular weights ranging between 3 x 10 4 and 4 x 10 6 daltons.
6. A use according to claim 5, wherein said monomers range between 2 x 10 5 and 2.4 x 10 6 daltons.
7. A use according to claim 1, wherein said hydroxyethyl starch comprises HES-1:10, HES-7-8:10 or HES-5:10.
8. A use according to claim 1, wherein said medicament includes a physiologically acceptable vehicle.
9. A use according to claim 8, wherein said vehicle comprises sterile water, saline or aqueous buffer solutions containing alkali or alkaline earth metal carbonates, phosphates, bicarbonates, citrates, borates, acetates, succinates and tromethamine (TRIS).
10. A use according to claim 8, wherein said vehicle comprises saline, phosphate buffered saline, citrate buffer, and Ringers lactate solution.
11. A use according to claim 1, wherein said medicament further comprises an effective amount of at least one pharmaceutically active agent.

- 12. A use according to claim 11, wherein said pharmaceutically active agent comprises an anti-adhesion formation agent, an antibiotic agent, an antihistaminic, an anti-inflammatory agent, antifungal agent, amoebocidal agent, trichomonacidal agent, antiprotozoal agent, an antiviral agent, antineoplastic agent or anti-inflammatory corticosteroid.
13. A use according to claim 12, wherein said anti-adhesion formation agent comprises a lazaroid, a retinoid, quinacrine, manoalide, a 5-lipoxygenase inhibitor, ketotifen, dipyridamole, a NSAID, or an anti-inflammatory corticosteroid.
14. A use according to claim 12, wherein said anti-inflammatory corticosteroid comprises betamethasone or dexamethasone.
15. A composition for reducing or preventing post-surgical adhesion formation comprising a pharmaceutically active agent and an anti-adhesion effective amount of hydroxyethyl starch.
16. The composition according to claim 15, wherein said hydroxyethyl starch comprises an amylopectin having hydroxyethyl groups which are substituted on a molar ratio ranging between 0.1 and 0.8 of a hydroxyethyl group per glucopyranose unit.
17. The composition according to claim 16, wherein said hydroxyethyl starch comprises amylopectin monomers of molecular weights ranging between 3 x 10 4 and 4 x 10 6 daltons.
18. The composition according to claim 17, wherein said monomers range between 2 x 10 5 and 2.4 x 10 6 daltons.
19. The composition according to claim 15, wherein said hydroxyethyl starch comprises HES-1:10, HES-7-8:10, or HES-5:10.
20. The composition according to claim 19, wherein said hydroxyethyl starch is present in an amount ranging between 0.1% and 60% (w/v).
21. The composition according to claim 20, wherein said hydroxyethyl starch is present in an amount ranging between 5.4% and 34.3% (w/v).

22. The composition according to claim 15, wherein said pharmaceutically active agent comprises an anti-adhesion formation agent.
23. The composition according to claim 15, wherein said anti-adhesion formation agent comprises a lazaroid, a retinoid, quinacrine, manoalide, a 5-lipoxygenase inhibitor, ketotifen, dipyridamole, a NSAID, or an anti-inflammatory corticosteroid.
24. The composition according to claim 23, wherein said anti-inflammatory corticosteroid comprises betamethasone or dexamethasone.
25. The composition according to claim 24, wherein said anti-inflammatory corticosteroid is present in an amount ranging between 0.00001 mg/ml and 50 mg/ml.
26. The composition according to claim 25, wherein said anti-inflammatory agent is present in an amount ranging between 0.001 mg/ml and 5 mg/ml.
27. The composition for use in reducing or preventing formation of post-surgicaladhesions comprising an anti-adhesion effective amount of hydroxyethyl starch.
28. The composition according to claim 27, wherein said hydroxyethyl starch comprises an amylopectin having hydroxyethyl groups which are substituted on a molar ratio ranging between 0.1 and 0.8 of a hydroxyethyl group per glucopyranose unit.
29. The composition according to claim 28, wherein said hydroxyethyl starch comprises amylopectin monomers of molecular weights ranging between 3 x 10 4 and 4 x 10 6 daltons.
30. The composition according to claim 28, wherein said monomers range between 2 x 10 5 and 2.4 x 10 6 daltons.
31. The composition according to claim 27, wherein said hydroxyethyl starch comprises HES-1:10, HES-7-8:10 or HES-5:10.
32. The composition according to claim 27, wherein said composition includes a physiologically acceptable vehicle.
33. The composition according to claim 32, wherein said vehicle comprises sterile water, saline or aqueous buffer solutions containing alkali or alkaline earth metal cabonates, phosphates, bicarbonates, citrates, borates, acetates, succinates andtromethamine (TRIS).
34. The composition according to claim 32, wherein said vehicle comprises saline, phosphate buffered saline, citrate buffer, and Ringers lactate solution.35. The composition according to claim 27, wherein said composition further comprises an effective amount of at least one pharmaceutically active agent.
36. The composition according to claim 35, wherein said pharmaceutically active agent comprises an anti-adhesion formation agent, an antibiotic agent, anantihistaminic, an anti-inflammatory agent, antifungal agent, amoebocidal agent,trichomonacidal agent, antiprotozoal agent, an antiviral agent, antineoplastic agent or anti-inflammatory corticosteroid.
37. The composition according to claim 36, wherein said anti-adhesion formation agent comprises a lazaroid, a retinoid, quinacrine, manoalide or an analog thereof, a 5-lipoxygenase inhibitor, ketotifen or an analog thereof, dipyridamole or an analog thereof, a NSAID, or an anti-inflammatory corticosteroid.
38. The composition according to claim 36, wherein said anti-inflammatory colticosteroid comprises betamethasone or dexamethasone.
CA2223573A 1995-06-07 1996-05-31 Use of hydroxyethyl starch to prevent post surgical adhesion and as an intracavity carrier device Expired - Fee Related CA2223573C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/482,235 US5807833A (en) 1995-06-07 1995-06-07 Hydroxyethyl starch and use thereof as an absorbable mechanical barrier and intracavity carrier device
US08/482,235 1995-06-07
PCT/US1996/008098 WO1996040168A2 (en) 1995-06-07 1996-05-31 Use of hydroxyethyl starch to prevent post surgical adhesion and as an intracavity carrier device

Publications (2)

Publication Number Publication Date
CA2223573A1 true CA2223573A1 (en) 1996-12-19
CA2223573C CA2223573C (en) 2011-09-20

Family

ID=23915271

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2223573A Expired - Fee Related CA2223573C (en) 1995-06-07 1996-05-31 Use of hydroxyethyl starch to prevent post surgical adhesion and as an intracavity carrier device

Country Status (9)

Country Link
US (1) US5807833A (en)
EP (1) EP0831856B1 (en)
JP (2) JP4184431B2 (en)
AT (1) ATE221782T1 (en)
AU (1) AU722836B2 (en)
CA (1) CA2223573C (en)
DE (1) DE69622863T2 (en)
ES (1) ES2177787T3 (en)
WO (1) WO1996040168A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032144A1 (en) * 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807833A (en) * 1995-06-07 1998-09-15 University Of Southern California Hydroxyethyl starch and use thereof as an absorbable mechanical barrier and intracavity carrier device
DK1085920T3 (en) * 1998-05-13 2002-04-15 Ml Lab Plc Dextrin-containing preparation for the prevention of surgical adhesions
GB9810127D0 (en) 1998-05-13 1998-07-08 Ml Lab Plc Prevention of surgical adhesions
EP1341467A4 (en) * 2000-12-05 2009-11-18 Haemonetics Corp Method for precipitating red blood cells
US7332179B2 (en) 2003-12-12 2008-02-19 Kimberly-Clark Worldwide, Inc. Tissue products comprising a cleansing composition
US7642395B2 (en) 2004-12-28 2010-01-05 Kimberly-Clark Worldwide, Inc. Composition and wipe for reducing viscosity of viscoelastic bodily fluids
US8414907B2 (en) 2005-04-28 2013-04-09 Warsaw Orthopedic, Inc. Coatings on medical implants to guide soft tissue healing
US9119901B2 (en) * 2005-04-28 2015-09-01 Warsaw Orthopedic, Inc. Surface treatments for promoting selective tissue attachment to medical impants
US20090062233A1 (en) 2007-08-09 2009-03-05 Xin Ji Modified starch material of biocompatible hemostasis
CN104888263B (en) * 2008-01-14 2018-11-30 北京环球利康科技有限公司 Biocompatible hemostatic prevents adhesion, promoting healing, the closed modified starch material of surgery
EP2832360A1 (en) 2013-07-30 2015-02-04 Fresenius Kabi Deutschland GmbH Polysaccharide for use in preventing metastasis formation and/or relapse

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE456346B (en) * 1984-07-23 1988-09-26 Pharmacia Ab GEL TO PREVENT ADHESION BETWEEN BODY TISSUE AND SET FOR ITS PREPARATION
EP0234897A3 (en) * 1986-02-24 1987-11-19 Ethicon, Inc. Inhibition of post-surgical adhesion formation by the continual topical administration of glucocorticoid
US4913903A (en) * 1987-02-04 1990-04-03 Alza Corporation Post-surgical applications for bioerodible polymers
US5080893A (en) * 1988-05-31 1992-01-14 University Of Florida Method for preventing surgical adhesions using a dilute solution of polymer
SE8900586L (en) * 1989-02-21 1990-08-22 Pharmacia Ab COMPOSITION AND PROCEDURES TO PREVENT ADHESION BETWEEN BODY TISSUE
US5219895A (en) * 1991-01-29 1993-06-15 Autogenesis Technologies, Inc. Collagen-based adhesives and sealants and methods of preparation and use thereof
JP3174400B2 (en) * 1992-05-28 2001-06-11 味の素ファルマ株式会社 Peritoneal washings
DE4242926C2 (en) * 1992-12-18 1994-12-15 Fresenius Ag Dialysis solution for peritoneal dialysis
US5807833A (en) * 1995-06-07 1998-09-15 University Of Southern California Hydroxyethyl starch and use thereof as an absorbable mechanical barrier and intracavity carrier device
US5639468A (en) * 1995-06-07 1997-06-17 University Of Southern California Method for reducing or preventing post-surgical adhesion formation using manoalide and analogs thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032144A1 (en) * 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources
WO2006032143A1 (en) * 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans

Also Published As

Publication number Publication date
JP2008264495A (en) 2008-11-06
ATE221782T1 (en) 2002-08-15
DE69622863T2 (en) 2002-12-12
JPH11506741A (en) 1999-06-15
AU722836B2 (en) 2000-08-10
JP4184431B2 (en) 2008-11-19
CA2223573C (en) 2011-09-20
EP0831856A2 (en) 1998-04-01
US5807833A (en) 1998-09-15
ES2177787T3 (en) 2002-12-16
EP0831856B1 (en) 2002-08-07
WO1996040168A3 (en) 1997-01-23
AU5956996A (en) 1996-12-30
WO1996040168A2 (en) 1996-12-19
DE69622863D1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
JP2008264495A (en) Use of hydroxyethyl starch to prevent post surgical adhesion and as intracavity carrier device
US5478837A (en) Use of quinacrine in preventing adhesion formation
Fredericks et al. Adhesion prevention in the rabbit with sodium carboxymethylcellulose solutions
KR100701721B1 (en) Topical treatment or prevention of ocular infections
US5126141A (en) Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
KR20070057698A (en) Topical otic compositions and methods of topical treatment or prevention of otic infections
CA2458853A1 (en) Use of fucans in the treatment of adhesions, arthritis and psoriasis
OA10744A (en) Controlled release of miotic and mydriatic drugs in the anterior chamber
EP0792153B1 (en) Compositions containing lazaroids and their use for preventing adhesions
US5498613A (en) Dipyridamole and analogs thereof in preventing adhesion formation
JPH11240838A (en) Treatment of ophthalmic infection by azithromycin
MXPA98010124A (en) Procedure to treat ocular infections with azitromic
US5639468A (en) Method for reducing or preventing post-surgical adhesion formation using manoalide and analogs thereof
Peck et al. Topics and trends in surgical research: evaluation of CMC and HA solutions for adhesiolysis
JP4276601B2 (en) Composition containing dextrin for inhibiting surgical adhesions
JP2729859B2 (en) Reversible thermogelling aqueous pharmaceutical composition
Rodgers et al. Reduction of adhesion formation in rabbits by intraperitoneal administration of lazaroid formulations.
US5891460A (en) Method for reducing or preventing post-surgical adhesion formation using ketotifen and analogs thereof
KR100740735B1 (en) Dextrin containing compositions for prevention of adhesions
HUT53806A (en) Process for inhibiting nephrotoxicity of aminoglycosides
US20040248928A1 (en) Pharmaceutical composition comprising an adenosine A1/A2 agonist and a sodium hydrogen exchanger inhibitor
Korell 6. Recent Advances in Adhesion Prevention
diZerega et al. Recent Advances in Adhesion Prevention
GB1593954A (en) Xanthan gum or locust bean gum topical therapeutic compositions
HU209955B (en) Process for producing pharmaceutical compositions containing tissue- -plasminogen-activator of poor solubility for inhibiting production and regeneration of deformities

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150601